Adverse reactions from community directed treatment with ivermectin (CDTI) for onchocerciasis and loiasis in Ondo State, Nigeria

Revista de Biologia Tropical

Volumn 56, Issue 4, 2008, Pages 1635-1643

  Otubanjo, O A ^a   Adeoye, G O ^a   Ibidapo, C A ^b   Akinsanya, B ^a   Okeke, P ^a   Atalabi, T ^a   Adejai, E T ^c   Braide, E ^d  

^a UNIVERSITY OF LAGOS   (Nigeria)

^b LAGOS STATE UNIVERSITY   (Nigeria)

^c Onchocerciasis Section   (Nigeria)

^d UNIVERSITY OF CALABAR   (Nigeria)

Author keywords

Adverse reactions; African Programme for Onchocerciasis Control; Community directed treatment with ivermectin; Loiasis; Onchocerciasis; Rapid assessment procedure for Loa loa

Indexed keywords

LOA LOA;

ANTIPARASITIC AGENT; IVERMECTIN;

ADOLESCENT; ADULT; AGED; ANIMAL; ARTICLE; ENDEMIC DISEASE; FEMALE; HUMAN; LOIASIS; MALE; MIDDLE AGED; NIGERIA; ONCHOCERCIASIS; PUBLIC HEALTH; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIPARASITIC AGENTS; ENDEMIC DISEASES; FEMALE; HUMANS; IVERMECTIN; LOIASIS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; NIGERIA; ONCHOCERCIASIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 70350018499     PISSN: 00347744     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Amazigo, U.V., O.M. Obono, K.Y. Dadzie, J. Remme, J. Jiya, R. Ndyomugyenyi, I.B. Rongon, M. Noma & A. Seketeli. 2002. Monitoring community directed treatment programmes for sustainability: lessons from the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasit. 96: 575-592
2. Awadzi K., N.O. Opokn, E.T. Addy & B.T. Quartey. 1995. The chemotherapy of onchocerciasis XIX: The chemical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol. 46: 31-7
3. Burnham, G.M. 1993. Adverse reactions to ivermectin treatment for onchorcerciasis: results of a placebo-controlled, double-blind trial in Malawi. Trans R Soc Trop Med Hyg. 87: 313-7
4. Baraka O.Z., A.K. Khier, K.M. Ahmend, M.M. Ali., A.E. el Mardi, B.M. Mahmoud, M.H. Ali., M.M. Homeida & J.F.Williams.1995. Community based distribution of ivermectin in eastern Sudan: acceptability and early post-treatment reactions. Trans R Soc Trop Med Hyg. 9: 316-8.
5. Boussinesq M., I. Gardon, N. Gardon-Wendel, I. Kamgno, P. Ngoumou & I.P. Chippaux 1998. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. Am J Trop Med Hyg. 58: 461-469.
6. Boussinesq M. I. Gardon, I. Kamgno & S.D.S. Pion. 2001. Relationship between the prevalence and intensity of Loa loa infection in the Central Province of Cameroon. Ann Trop Med Parasit. 95: 495-507.
7. Clemmons L., U.V. Amazigo, A.C. Bissek, M. Noma, U. Oyene, U. Ekpo, J. Msuya-Mpanju, S. Katenga & A. Seketeli. 2002. Gender issues CDTI of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasit. 96: S59-S74.
8. Chippaux J.P., M. Boussinesq, J. Gardon, N. Gardon-Wendel & J.C. Ernould.1996. Severe adverse reaction risk during mass treatment with ivermectin in loiasisendemic areas. Parasitol. Today.12: 448-450.
9. Clemmons L.U.V. Amazigo, A.C. Bissek, M. Noma, U. Oyene, J. Msuya-Mpanju, S. Katenga & A. Seketeli. 2002. Gender issues in community -directed treatment with ivermectin CDTI of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasit. 96: S59-S74.
10. Ety'ale D. 2001.Vision 2020: update on onchocerciasis community. Eye Health. 14: 19-20.
11. Etay'ale D. 2002. Eliminating onchocerciasis as a public health problem: the beginning of the end. Brit J Opthamol. 86: 844-846
12. Gardon J., N. Gardon-Wendel, Demangangangue, J. Kamgno, J.P. Chippaux & M. Boussinesq. 1997. Serious reactions after mass treatment of onchocerciasis with ivermectin in an endemic area for Loa loa infection. Lancet. 350: 18-22.
13. Idowu E.T. 2004. Epidemiological, clinco-parasitological and control studies of onchocerciasis in selected communities of Ondo state, Nigeria. Ph.D. Thesis, University of Lagos, Nigeria.
14. Kipp W., J. Bamhuhiiga, T. Rubaale & D.W. Buttner. 2003. Adverse reaction to ivermectin treatment in Simulium neavei-transmitted onchocerciasis Am J Trop Med Hyg.69: 621-3.
15. Oyibo W.A. & A.F. Fagbenro-Beyioku. 2003. Adverse reaction following annual ivermectin treatment of onchcerciasis in Nigeria. Int J Infect Dis. 7: 156-9
16. Seketeli A., G. Adeoye, A. Eyamba, E. Noruka, P. Drameh, U.V. Amazigo, M. Noma, F. Agboton, Y. Ahoton, O. Kale & K.Y. Dadziek. 2002 The achievement and challenges of the African programme for onchocerciasis control (APOC). Ann Trop Med Parasit. 96: S15-S28.
17. Turner, P.F., K.A. Rocket, E.A. Otlesan, H. Francis, K. Awadzi & I. Clark. 1994. Inter leukin-6 and tumor necrosis factor in the pathogenesis of adverse reactions after treatment of lymphatic filariasis and onchocerciasis. J Infect Dis 69: 1071-5.
18. Tropical Disease Research 2000.World Health Organization (WHO) Implementation and sustainability of community directed treatment with ivermectin. Geneva. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Disease. TDR/AFR/RP/96.1.
19. Tropical Disease Research (TDR). 2002. Guidelines for rapid assessment of Loa loa. UNDP/World Bank/WHO.TDR/IDE/RAPLOA/02. 138 p.
20. World Health Organization 2003. Report of a multicountry study: The involvement of community-directed ditributors of ivermectin in other health and development activities. UNDP/World Bank/WHO TDR/IDE/CDD1/03.1.
21. Zea-Flores R, Richards FO Jr. Gonzalez-Peralta C, Castro Ramirez J, Zea-Flores G., Collins RC, Cupp E.1992. Adverse reactions after community treatment onchorcerciasis with ivermectin in Guatamela. Trans R Soc Trop Med Hyg. 86: 663-6.